Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : iPSC-based Cell Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eterna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eterna and Factor Bioscience Partner for Cell Therapy in Oncology and Rare Diseases
Details : Under the terms of the agreement, Eterna has exclusive license to develop and market certain iPSC-based cell therapy products utilizing Factor’s cell reprogramming and gene-editing technologies.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 17, 2024
Lead Product(s) : iPSC-based Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eterna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : mRNA-based iPSC-derived Macrophage
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting, allogeneic iPS cell-derived cytotoxic lymphocytes, and advanced targeted insertion technologies.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 16, 2022
Lead Product(s) : mRNA-based iPSC-derived Macrophage
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Brooklyn ImmunoTherapeutics
Deal Size : $1.0 million
Deal Type : Licensing Agreement
Details : The deal would allow Brooklyn to utilize an extensively patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, non-immunogenic and non-mutagenic, for treatment of several solid tumor and...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Brooklyn ImmunoTherapeutics
Deal Size : $1.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?